Ceribell CTO Raymond Woo sells $119,145 in company stock
Raymond Woo, CTO of Ceribell, Inc. (NASDAQ:CBLL), sold 4,887 shares of company stock for $119,145 after exercising stock options. Despite the company's impressive gross profit margins, analysts do not anticipate profitability this year. Several analyst firms have recently raised their price targets for Ceribell, citing growth drivers and leadership in point-of-care rapid EEG technology.
Form 4 CeriBell Inc For: 2 October
This article from Investing.com reports on a Form 4 filing for CeriBell Inc, dated October 2. Form 4 filings disclose changes in beneficial ownership of a company's securities by insiders, such as officers, directors, and significant shareholders. The brief piece indicates that CeriBell Inc's stock symbol is CBLL.
Ceribell CTO Raymond Woo sells $119,145 in company stock By Investing.com
Raymond Woo, CTO of Ceribell, Inc. (NASDAQ:CBLL), sold 4,887 shares of company stock for $119,145. This transaction followed the exercise of stock options and was executed under a Rule 10b5-1 trading plan. Despite the stock's 100% return over the past year, InvestingPro suggests it may be overvalued, although analysts from TD Cowen, BTIG, and Raymond James have recently raised price targets and maintained positive ratings for Ceribell.
Ceribell CTO Raymond Woo sells $119,145 in company stock By Investing.com
Ceribell CTO Raymond Woo sold 4,887 shares of company stock worth $119,145 on October 1, 2026, after exercising stock options. Despite the stock's 100% return over the past year, InvestingPro suggests it may be overvalued, and analysts do not anticipate profitability for Ceribell this year. Several analyst firms, including TD Cowen, BTIG, and Raymond James, have recently raised their price targets for Ceribell, citing positive outlooks and new growth drivers.
SSM Health touts seizure detection technology
SSM Health in Southern Illinois is now the first healthcare provider in the region to offer the Ceribell System, an FDA-cleared EEG technology for rapid detection of non-convulsive seizures. This system enhances neurological care for critically ill patients by providing faster diagnosis and treatment closer to home, available at SSM Health Good Samaritan Hospital in Mount Vernon and SSM Health St. Mary’s Hospital in Centralia. The technology helps clinicians quickly assess brain activity and continuously monitor patients, reducing the need for transfers and improving outcomes for challenging-to-detect non-convulsive seizures.
Option exercises accompany a 4,887-share sale at $24.38 by Ceribell (CBLL) CTO Raymond Woo.
Ceribell CTO Raymond Woo exercised options on October 1, 2026, to acquire a total of 4,887 shares (4,864 shares at $3.65 and 23 shares at $4.70) and subsequently sold all 4,887 shares at $24.38 per share. These transactions were executed under a Rule 10b5-1 trading plan adopted on June 5, 2026, and resulted in approximate gross sale proceeds of $119K and a pre-tax spread of $101K. After the transactions, Woo holds 67,658 stock option contracts and 203,118 common stock shares.
CeriBell Is Maintained at Buy by TD Cowen
This article states that TD Cowen has maintained its Buy rating for CeriBell. The content of the article itself is missing, so no further details can be provided.
TD Cowen maintains Buy rating on CeriBell, $33 price target
TD Cowen has reiterated its Buy rating on CeriBell's stock, setting a price target of $33.00, which suggests a 39.8% upside from its recent closing price. The positive outlook is attributed to the anticipated improvement in CeriBell's sales force productivity and the significant market opportunity for its Ceribell System in critical care settings.
Form 144 Ceribell For: 1 October By Investing.com
This article from Investing.com reports on a Form 144 filing for Ceribell on October 1st, 2026. Form 144 is a notice of the intent to sell restricted securities. The article does not provide specific details about the transaction or the individuals involved.
Ceribell Officer Raymond Woo Files Form 144 for Proposed Sale of 4,887 Shares
Ceribell officer Raymond Woo has filed a Form 144 to propose the sale of 4,887 shares of Ceribell common stock, valued at $119,145.06, through Fidelity Brokerage Services LLC on the NASDAQ exchange. These shares were acquired via a stock option exercise on October 1, 2026, with cash payment, and the sale is under a Rule 10b5-1 trading plan established in June 2026. Woo previously sold shares in August and September 2026, and the company reports 38,378,101 common shares outstanding.
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
Ceribell has received FDA 510(k) clearance for new software for its Ceribell System, enhancing the interpretation of longitudinal brain activity. This software introduces Alpha-Delta Ratio & Relative Alpha Trending, Burst Suppression Monitoring, and Amplitude-Integrated EEG analysis, making it faster and easier for clinicians to identify changes in brain activity across all age groups. These updates aim to improve proactive intervention and safe sedation adjustments, building on Ceribell's AI-powered EEG platform expansion.
Ceribell receives FDA clearance for new EEG software features
Ceribell, Inc. has received FDA clearance for new software features for its Ceribell System, which will enable clinicians to interpret longitudinal brain activity data. The update includes Alpha-Delta Ratio and Relative Alpha Trending, Burst Suppression Monitoring, and Amplitude-Integrated EEG, applicable across all age groups from premature newborns to adults. These features are designed to enhance continuous brain monitoring and neurological assessment in acute-care settings and are expected to be integrated through an automatic software update in the first half of 2027.
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
Ceribell has received FDA 510(k) clearance for new software for its Ceribell System, enhancing the interpretation of brain activity for clinicians. The software introduces Alpha-Delta Ratio (ADR) & Relative Alpha (RA) Trending, Burst Suppression (BS) Monitoring, and Amplitude-Integrated EEG (aEEG), designed to simplify continuous EEG interpretation at the bedside. This clearance has no age restriction, making the technology applicable to patients from premature newborns to adults, and is expected to be integrated through an automatic software update in the first half of 2027.
BTIG Maintains Ceribell(CBLL.US) With Buy Rating, Maintains Target Price $30
BTIG has reiterated its Buy rating for Ceribell (CBLL.US) and maintained a target price of $30. This indicates a continued positive outlook from the firm regarding the company's stock performance.
Ceribell stock price target reiterated at $30 by BTIG on growth outlook
BTIG has reiterated its Buy rating and a $30.00 price target for Ceribell (NASDAQ: CBLL) stock, following recent investor meetings with company management. The firm is encouraged by Ceribell's commercial strategy, Veterans Affairs expansion, pediatric and neonate ramp, upcoming delirium launch, pipeline updates, and a clear path to profitability, expressing confidence in growth drivers extending into 2027. Ceribell's impressive 88.9% gross profit margin and ongoing expansion into new market indications underpin BTIG's positive outlook despite the stock trading near its 52-week high and being considered potentially overvalued by InvestingPro analysis.
Ceribell (CBLL) CEO sells stock under a preset 2025 trading plan
Ceribell, Inc. CEO Chao Xingjuan sold 20,846 shares of common stock at a weighted average price of $25.03 per share on September 15, 2026. This transaction was executed under a Rule 10b5-1 trading plan adopted on September 12, 2025. Following the sale, Ms. Xingjuan directly holds 746,345 shares and indirectly holds 369,088 shares through the ACP 2021 Trust.
Ceribell (CBLL) CFO sells 846 shares under 10b5-1 plan
Ceribell's CFO, Scott Blumberg, exercised stock options for 846 shares at $9.41 per share and subsequently sold all 846 shares at a weighted average price of approximately $25 per share on September 15, 2026. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these transactions, Blumberg still holds 51,802 fully vested and exercisable stock options.
Blumberg Scott Executes 846 Ceribell Options and Disposes Shares on September 15, 2026
On September 15, 2026, Blumberg Scott exercised options for 846 Ceribell (NASDAQ:CBLL) shares at $9.41 each and simultaneously sold them for $25 per share. After these transactions, Blumberg Scott's Ceribell holdings were adjusted to 146,600 shares, and derivative securities ownership became 51,802. These activities reflect changes in investor holdings and percentages for Ceribell.
Ceribell CFO Scott Blumberg exercises options, sells $21,150 in stock. By Investing.com
Ceribell CFO Scott Blumberg sold $21,150 worth of company stock on September 15, 2026, after exercising options for 846 shares. These transactions were executed under a Rule 10b5-1 trading plan, and Mr. Blumberg now directly holds 146,600 shares and beneficially owns 51,802 stock options. The sale occurred while Ceribell shares were near their 52-week high, with InvestingPro analysis indicating the stock is overvalued.
Ceribell CTO Raymond Woo sells $118,900 of company stock By Investing.com
Raymond Woo, CTO of Ceribell, Inc. (CBLL), sold $118,900 worth of company stock on September 8, 2026, through a pre-planned trading arrangement, while also acquiring shares via stock options. The sale occurred as Ceribell's stock surged over 100% in the past year, though InvestingPro deems it overvalued. The company recently reported a 33% revenue increase for Q2 2026, and analysts from Canaccord, Raymond James, and BTIG have raised their price targets due to growth in seizure-detection and new product developments.
BTIG reiterates Ceribell stock rating at buy, $30 price target
BTIG has reiterated its Buy rating and $30 price target for Ceribell (NASDAQ:CBLL), citing the company's market leadership in point-of-care rapid EEG, strong financial performance, and positive physician feedback on its new Delirium Monitor. The firm anticipates a long runway of growth for Ceribell, driven by new product launches and an expanding platform. This outlook is supported by recent Q2 2026 revenue growth of 33% and FDA approval for expanded indications.
Ceribell senior VP sells $224,451 of company stock By Investing.com
David Foehr, Senior VP at Ceribell, Inc., sold $224,451 worth of company stock after acquiring 7,500 shares through stock options. This sale follows a significant stock performance but occurs while InvestingPro analysis suggests the stock is overvalued. Despite this, Ceribell reported strong Q2 2026 revenue growth, and multiple firms have raised price targets, maintaining a positive outlook.
BTIG reiterates Ceribell stock rating at buy, $30 price target By Investing.com
BTIG has reiterated its Buy rating and $30 price target for Ceribell (NASDAQ:CBLL), citing the company's strong growth trajectory, market leadership in point-of-care rapid EEG, and positive feedback on its new Delirium Monitor. Despite concerns about potential overvaluation from InvestingPro, the firm believes Ceribell is poised for continued growth driven by its expanding platform and FDA approvals. Other analysts, Canaccord and Raymond James, also recently raised their price targets for Ceribell based on strong Q2 2026 revenue and new growth drivers.
Ceribell CTO Raymond Woo sells $118,900 of company stock
Ceribell CTO Raymond Woo sold $118,900 worth of company stock on September 8, 2026, through a pre-planned trading arrangement. This sale occurred after the company's shares had more than doubled in the past year, despite an InvestingPro analysis indicating the stock is currently overvalued. Woo also acquired shares by exercising stock options, and after these transactions, he directly holds 203,118 shares of Ceribell.
Ceribell CEO Chao Xingjuan Executes Options and Sells 39,540 Shares at $24.61, Retains 767,191 Shares
Ceribell CEO Chao Xingjuan exercised options for 25,000 shares at $4.70 each and simultaneously sold 39,540 shares at $24.61 per share on September 2, 2026. After these transactions, Xingjuan retains ownership of 767,191 shares of Ceribell (NASDAQ:CBLL) and holds 30,815 derivative securities. These activities resulted in a reduction of her direct share ownership while maintaining a significant stake in the company.
Ceribell CEO Chao Xingjuan sells $973,079 in company stock By Investing.com
Ceribell CEO Chao Xingjuan sold 39,540 shares of company stock worth approximately $973,079 at a weighted average price of $24.61 per share. Concurrently, she acquired 25,000 shares through stock option exercises for $117,500. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan and occurred while the stock traded near its 52-week high, having gained 100% over the past year.
Ceribell CEO Chao Xingjuan sells $973,079 in company stock By Investing.com
Ceribell (CBLL) CEO Chao Xingjuan sold 39,540 shares of company stock for approximately $973,079, while also acquiring 25,000 shares through option exercises totaling $117,500, all under a pre-arranged trading plan. The sales occurred as the stock traded near its 52-week high after a 100% gain over the past year, with InvestingPro suggesting the stock is overvalued. Despite recent losses per share, analysts from Canaccord, Raymond James, and BTIG have raised their price targets and maintained "Buy" ratings for Ceribell, citing strong revenue growth and leadership in rapid EEG.
Ceribell CEO Chao Xingjuan sells $973,079 in company stock
Ceribell, Inc. CEO Chao Xingjuan sold 39,540 shares of company stock for approximately $973,079 on September 2, 2026, while also acquiring 25,000 shares through option exercises. These transactions were part of a pre-arranged trading plan, and Xingjuan retains significant holdings in the company. The sales occurred as Ceribell's stock traded near its 52-week high, following strong recent financial results and positive analyst outlooks.
Ceribell CFO Scott Blumberg sells $16,300 in common stock
Ceribell, Inc. CFO Scott Blumberg sold 652 shares of company stock for $16,300 after exercising options. The transaction occurred while the stock traded near its 52-week high, following a 100% return over the past year. This comes amid positive analyst outlooks and strong Q2 2026 revenue growth for Ceribell.
Raymond James raises Ceribell stock price target on new growth drivers
Raymond James has increased its price target for Ceribell (NASDAQ:CBLL) to $29.00 from $24.00, reiterating a Strong Buy rating, due to new growth opportunities in neonates, pediatrics, and delirium applications. The firm also noted Ceribell's new products like a headband, full montage, and recorder which enhance its competitive position. Despite lagging peers year-to-date, analysts expect the stock to perform well, driven by its impressive 89% gross profit margins and recent FDA approvals for expanded use.
Ceribell CFO Blumberg sells $36,534 in stock
Ceribell's CFO, Scott Blumberg, sold 1,521 shares worth $36,534 on August 21, 2026, to cover tax obligations related to restricted stock units. This transaction occurred as the company's shares traded near their 52-week high after a significant 109% gain over the past year. Despite a Q2 2026 loss per share, Ceribell reported a 33% increase in revenue, and analysts maintain positive outlooks with raised price targets due to the company's growth in seizure detection and new product development.
Ceribell (CBLL) CFO sells 1,521 shares to cover taxes
Ceribell, Inc.'s Chief Financial Officer, Scott Blumberg, sold 1,521 shares of common stock at $24.02 per share on August 21, 2026. This transaction was executed to cover tax withholding obligations associated with the vesting of restricted stock units. After the sale, Blumberg directly holds 146,600 shares of Ceribell common stock.
Ceribell senior VP Foehr sells $44,424 in company stock
David Foehr, Senior Vice President of Finance at Ceribell, Inc. (NASDAQ:CBLL), sold company stock worth $44,424 in two transactions in late August. These sales were made to cover tax obligations and through a Rule 10b5-1 trading plan, leaving him with 35,899 shares. The company recently reported strong Q2 2026 revenue growth of 33%, and analysts have raised price targets for the stock.
Ceribell CTO Raymond Woo sells $47,535 in company stock
Ceribell CTO Raymond Woo sold 1,979 shares of the company's stock for $47,535 to cover tax obligations related to restricted stock units. This sale occurred while the stock was near its 52-week high, having returned 109% over the past year. Despite a recent quarterly loss, Ceribell reported a 33% revenue increase, leading analysts to raise price targets.
Ceribell (CBLL) CTO sells shares to cover RSU taxes
Ceribell, Inc.'s Chief Technology Officer, Raymond Woo, sold 1,979 shares of common stock at $24.02 per share on August 21, 2026. This transaction was executed to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). After the sale, Woo directly holds 194,729 shares, which includes shares acquired through an Employee Stock Purchase Plan.
Ceribell president and CEO Chao Xingjuan sells $145,753 in stock
Ceribell President and CEO Chao Xingjuan sold 6,068 shares of company stock for $145,753 to cover tax obligations from RSU vesting. This transaction comes as Ceribell shares are near their 52-week high after a 109% return over the past year. The company recently reported strong Q2 2026 revenue growth and received FDA approval for expanded indications, leading analysts to raise price targets.
Ceribell (NASDAQ: CBLL) CRO sale covers RSU tax bill only
Ceribell, Inc.'s Chief Revenue Officer, Joseph S. Manni, sold 1,361 shares of common stock at $24.02 per share on August 21, 2026. This sale was explicitly made to cover tax withholding obligations associated with vested restricted stock units (RSUs), not as a discretionary sale. Following the transaction, Manni directly holds 55,956 shares, including shares acquired through the company's Employee Stock Purchase Plan.
Ceribell (CBLL) insider offloads 1,852 shares via RSU tax and 10b5-1 sales
David Foehr, Senior VP, Finance and PAO at Ceribell, Inc. (CBLL), sold a total of 1,852 shares of common stock in August 2026. These sales included 993 shares sold to cover tax withholding obligations related to vesting RSUs and 859 shares sold under a Rule 10b5-1 trading plan. The transactions were direct holdings and occurred at prices of $24.02 and $23.95 per share respectively.
CeriBell, Inc. - Common Stock (CBLL) Stock Price, News, Quote & History
This article provides comprehensive financial information, news, and history for CeriBell, Inc. (CBLL) common stock. It details the company's focus on innovative diagnostic solutions for neurological disorders, including expansions of its EEG platform for delirium and pediatric patients, recent earnings reports, and FDA clearances for advanced detection technologies. The company has reported strong revenue growth and raised its full-year outlook, reflecting increased hospital account usage and new customer additions.
Ceribell CEO sells $841,292 in company stock
Ceribell CEO Chao Xingjuan sold $841,292 worth of company stock in August 2026 through a Rule 10b5-1 trading plan. These sales occurred shortly after the stock reached a 52-week high, following a 108% gain over the past year. Despite a wider-than-expected Q2 loss, Ceribell reported a 33% revenue increase and positive analyst ratings, driven by growth in seizure detection and new product developments.
Ceribell CFO Scott Blumberg sells over $863k in company stock
Ceribell's CFO, Scott Blumberg, sold over $863,000 worth of company stock after exercising stock options. These transactions, conducted under a pre-arranged trading plan, occurred when the stock was near its 52-week high and had seen a 108% return. Despite strong revenue growth, Ceribell reported a wider-than-expected loss, though analysts have raised price targets due to the company's market leadership and recent FDA approval for pediatric and neonate indications.
Ceribell CFO Scott Blumberg sells over $863k in company stock
Ceribell CFO Scott Blumberg sold over $863,000 worth of company stock in August 2026, following the exercise of stock options. The sales occurred when the stock was near its 52-week high, after a significant 108% return over the past year. These transactions, executed under a pre-arranged trading plan, left Blumberg directly holding 148,121 shares.
Ceribell (CBLL) updates insider trading report
Ceribell, Inc. (CBLL) has filed an amended Form 4/A with the SEC, updating an insider trading report. The amendment clarifies previous errors in reporting stock option amounts for Chief Financial Officer Scott Blumberg, specifically addressing the omission of incentive stock option portions. This filing ensures accurate reporting of beneficial ownership following his exercise of 36,000 shares under a 10b5-1 trading plan.
Ceribell (CBLL) CFO sells 34,502 shares near $25 under 10b5-1 plan
Ceribell, Inc. (CBLL) CFO Scott Blumberg exercised stock options for 34,502 shares and subsequently sold all 34,502 shares at an average price of around $25 per share between August 18–19, 2026. These transactions were executed under a Rule 10b5-1 trading plan adopted on December 12, 2025. Following these transactions, Blumberg directly holds 148,121 shares of common stock and 90,524 shares of stock options.
Scott Blumberg Sells 33,512 Shares of CeriBell (NASDAQ:CBLL) Stock
CeriBell CFO Scott Blumberg sold 33,512 shares of the company's stock, valued at $838,805.36, decreasing his position by 18.45%. This sale follows a previous transaction of 990 shares. Despite the sell-off, analysts maintain a "Moderate Buy" consensus for CBLL, with a target price of $22.40, even as the company's shares traded down following a recent earnings report that missed EPS estimates but exceeded revenue forecasts.
Insider Selling: CeriBell (NASDAQ:CBLL) CFO Sells $24,750.00 in Stock
CeriBell CFO Scott Blumberg sold 990 shares of the company's stock for $24,750 on August 18th, and an additional 33,512 shares for $838,805 on August 19th, reducing his direct holdings. Despite these insider sales and a quarterly EPS miss, CeriBell's revenue exceeded expectations, and analysts generally maintain a "Moderate Buy" rating, although the average price target is below the current share price. The company specializes in newborn hearing screening devices and has seen some institutional investment changes.
CeriBell (NASDAQ:CBLL) CEO Sells 2,199 Shares
CeriBell CEO Xingjuan Chao recently sold 2,199 shares of the company's stock for $54,975, reducing her ownership by 0.27%. This sale is part of several recent transactions by the CEO, including a larger sale of 31,415 shares the following day. Despite these insider sales, analysts generally maintain a "Moderate Buy" rating for CBLL with an average price target of $22.40, even though the company reported a quarterly loss that missed estimates.
Ceribell (CBLL) CEO sells 33,614 shares in 10b5-1 trades
Ceribell (CBLL) President and CEO Chao Xingjuan sold a total of 33,614 shares of common stock on August 18-19, 2026, at prices around $25 per share, under a Rule 10b5-1 trading plan. The transactions included 31,415 shares sold on August 19 at a weighted average price of $25.03, and 2,199 shares sold on August 18 at $25.00. Xingjuan also reported an indirect holding of 369,088 shares through the ACP 2021 Trust, disclaiming beneficial ownership except for her pecuniary interest.
CeriBell (CBLL) Institutional Ownership 2026 $CBLL
This article details the institutional ownership changes for CeriBell (CBLL) throughout 2026, including a table listing major shareholders, their shares held, market value, and quarterly changes. It also summarizes institutional buying and selling activities over the past two years, identifying the largest institutional investors and those with the highest volume of purchases and sales.
BTIG raises Ceribell stock price target to $30 on growth outlook
BTIG has raised its price target for Ceribell (NASDAQ:CBLL) to $30 from $28, maintaining a Buy rating, citing the company's market leadership in point-of-care rapid EEG and recent FDA approval for pediatric and neonate expansion. A BTIG survey indicates a 30% compound annual growth rate in headband volume between 2025 and 2028, further supported by the upcoming full launch of the Ceribell Delirium Monitor and strong Q2 2026 revenue growth of 33%. Despite a wider-than-expected Q2 loss, analysts view the company's advancements in seizure detection and new products favorably.
